

Index

LC = locus coeruleus; NE = norepinephrine

- acetylcholine
 - effects on LC activity 57–58
 - expression and receptor distribution in the LC 18
 - acetylcholine-containing neurons, inputs to the LC 57–58
 - addictions, NE gene-linked susceptibility 496 *see also* substance abuse
 - ADHD (attention deficit/hyperactivity disorder) 85–86
 - α_2 adrenergic receptor agonist treatment 563
 - amphetamine treatment 563
 - arousal state disorders 179
 - catecholamine dysregulation 179
 - cognitive disorders 418–420
 - effects of mode of LC activity 179
 - factors involved in etiology 557
 - genetic factors 561–562
 - heritability 561–562
 - history of descriptions and treatments 557–561
 - hypertonic LC activity 219–220
 - mechanisms of treatments 418–420
 - methylphenidate treatment 563
 - NE gene-linked susceptibility 493–494
 - prefrontal cortex dysfunction 418–420
 - pharmacological regulation of LC activity mode 224–225
 - possible genetic effects 419–420
 - reboxetine treatment 124, 125
 - role of compromised NET function 134–135
 - role of NE in etiology and treatment 418–420
 - role of NE in pathophysiology 563–564
 - role of NE in “prefrontal” abnormalities 562–563
 - role of NE system abnormalities 301
 - role of prefrontal cortex pathology 562–563
 - role of the dopamine system 563–564
 - role of the LC in pathophysiology 563–564
 - sleep disorders associated 176–177, 179
 - stimulants versus selective NE medications 563
- ADHD and NE medications 564–570, 573, 575–576, 578–579, 580, 581–582, 583
- α_2 agonists 574, 575–576
 - atomoxetine 577–582, 583, 584
 - bupropion 574–577, 578–579
 - monoamine oxidase inhibitors (MAOIs) 572, 573
 - review of studies 564–565, 567–570, 573, 575–576, 578–579, 580, 581–582
 - stimulants versus NE agents 565–566
 - tricyclic antidepressants 566–570, 572
 - venlafaxine 577, 580
- adrenal medulla 395
- adrenergic receptor genes 477–478, 479, 487–489
- adrenergic receptors
 - clinical effects of blocking by antidepressants 527–530
 - clinical effects of blocking by antipsychotics 527–530
 - functions 68
 - G protein-coupled receptors 68–69
 - historical development of classification 69–71
 - in the prefrontal cortex 408–409
 - mediation of norepinephrine and epinephrine actions 68
 - subtype-selective agents 69–71
 - subtypes 68, 69–71
 - see also* α_1 adrenergic receptors; α_2 adrenergic receptors; β adrenergic receptors; noradrenergic receptors

aging
 - and LC neuron loss 17, 180
 - and memory loss 415–416
 - effects on LC-NE activity 180
 - effects on sleep-wake regulation 180

alcoholism *see* substance abuse

α_1 adrenergic receptors
 - activation of CREB-mediated gene transcription 102–103
 - blocking effects of antidepressants 525, 526, 528
 - blocking effects of antipsychotics 525, 527, 529
 - densities in brain tissues 82–83
 - desensitization (tachyphylaxis) 74

629 Index

- G protein activation 79, 80
- genes 479, 487
- historical development of classification 69–71
- molecular characteristics 72–74
- nonsubtype selective agonists 71–72
- nonsubtype selective antagonists 71–72
- pharmacological characteristics 71–72
- physiological roles 80, 82–83
- polymorphisms 83
- regulation 74–75
- role in CNS function 82–83
- signal transduction pathways 79, 80
- subtype selective agents 71, 72
- α_2 adrenergic receptors
 - blocking effects of antidepressants 525, 526, 528
 - blocking effects of antipsychotics 525, 527, 529
 - densities in brain tissues 83, 86
 - desensitization (tachyphylaxis) 76–77
 - G protein activation 79–81
 - genes 479, 487–488
 - historical development of classification 69–71
 - in aetiology and treatment of depression 76–77
 - mechanisms of antidepressant drugs 76–77
 - mediation of analgesia 80, 84
 - mediation of anesthesia 80, 84
 - molecular characteristics 73, 76
 - nonsubtype selective agonists 73, 75–76
 - nonsubtype selective antagonists 73, 75–76
 - pharmacological characteristics 73, 75–76
 - physiological roles 80, 83–86
 - polymorphisms 86
 - regulation 76–77
 - signal transduction pathways 79–81
 - subtype selective agents 73, 75–76
 - subtype-specific functions 80, 83–86
 - α_2 agonists, ADHD treatment 574, 575–576
- Alzheimer's disease
 - cellular changes in the LC 19
 - cognitive deficits 416
 - degenerative process 416
 - inflammatory component 464
 - neuron loss in the LC 17, 18–19, 20, 180, 223–224
 - NE gene-linked susceptibility 493
 - postmortem brain research 341–342
 - role of compromised NET function 134–135
 - specific patterns of LC neuronal loss 463, 464
- amphetamine
 - effects of prolonged use on NET activity 131
 - effects on memory consolidation 238–240
 - effects on NETs 124, 125
 - treatment for ADHD 563
 - see also* substance abuse
- amygdala
 - axonal projection to the pericoerulear area 53
 - basolateral complex role in memory 237
- amygdala noradrenergic system
 - α adrenoceptor mediation of NE effects 247–248, 249, 250
 - β adrenoceptor mediation of NE effects 247–248, 249, 250
- BLA role in memory consolidation 244–245, 247–248, 249–250, 251–254, 256, 257, 259, 260, 261
- effects on neuroplasticity 249–251, 252–253
- electrophysiological events induced by activation 249–251
- influence of NE on memory consolidation 243–246, 247, 248, 250, 253
- influence on memory consolidation 243–246, 247, 248, 250, 253
- influences on different forms of memory 252–253
- influences on the hippocampus 252–253
- interaction with the cholinergic system 258–260, 261
- interactions with other systems on memory consolidation 253–254, 256, 257, 259, 260, 261
- mediation of epinephrine-induced memory enhancement 243–244
- mediation of GABAergic system effects on memory 258
- mediation of glucocorticoid hormone effects on memory 253–254, 256, 257
- mediation of opioid peptidergic system effects on memory 256–258, 259
- molecular events induced by activation 249–251
- regulation of memory processes in other brain regions 251–253
- role in memory 237
- stress-induced NE release and memory consolidation 245–246, 247
- training-induced NE release and memory consolidation 245–246, 247
- analgesia, mediation by α_2A adrenergic receptors 80, 84
- anesthesia
 - mediation by α_2A adrenergic receptors 80, 84
 - role of noradrenergic mechanisms 396–397
- animal models of psychopathology
 - approach to development of models 325
 - benefits and limitations of models 325–326
 - construct validity 301–302
 - convergent validity 301–302
 - criteria for a satisfactory model 301–302
 - etiological validity 301–302
 - face validity 301–302
 - future directions 326–327
 - NE system alterations 302–304, 325
 - predictive validity 301–302
 - role of NE in neural development 325
 - vulnerability to psychopathologies 325
- animal models of psychopathology (animal assay) 303–304, 317–320
 - benefits and limitations of models 325–326
 - elevated plus-maze 318
 - forced-swim test 317–318
 - open-field test 318–319
 - operant conflict test 320
 - social interaction test 319

630 Index

- animal models of psychopathology (breeding to phenotype) 303–304, 320–322
- benefits and limitations of models 326
- Flinders sensitive line 320–321
- Maudsley line 321
- Roman high- and low-avoidance rats 321–322
- animal models of psychopathology (gene manipulation) 303–304, 322–325
 - α_1 B adrenergic receptor knockout and overexpressing mice 323
 - α_2 adrenergic receptor knockout and overexpressing mice 323–324
 - benefits and limitation of models 326
 - dopamine β -hydroxylase knockout mice 322
 - galanin overexpressing mice 324–325
 - NET knockout mice 322–323
- animal models of psychopathology (homologous) 302–304, 317
 - adult models of psychopathology 314–317
 - chronic variable stress/chronic mild stress 315–316
 - early malnutrition 309–311
 - isolation rearing 311–313
 - learned helplessness 314–315
 - maternal separation and neonatal handling 307–309
 - neonatal infection 313
 - olfactory bulbectomy 316–317
 - perinatal models of psychopathology 302–314
 - plasticity of early life effects 313–314
 - prenatal glucocorticoid exposure 307
 - prenatal stress 306–307
- anorexia nervosa
 - NE metabolism 597–599
 - NE pharmacology in treatment 603
 - research on NE and feeding 595–597
- anterior cingulate cortex, influence on LC neuronal activity 215, 216, 217
- antidepressant drug research and development
 - actions on NE transporter 516–520
 - bi-dimensional model of affective illness 517–520
 - biogenic amine hypothesis of affective illness 516
 - discovery of chlorpromazine 515
 - discovery of imipramine 515–517
 - discovery of noradrenergic interactions 515
 - effects on adrenergic receptors 517–520
 - history of reserpine 516
 - in the 1950s and 1960s 515–517
 - in the 1970s and 1980s 517–520
 - introduction of monoamine oxidase inhibitors 515–517
 - introduction of the first antidepressants 515
 - introduction of tricyclic antidepressants 515
 - mechanisms of antidepressant actions 517–520
 - NE uptake blockers 516–520
 - permissive hypothesis of affective illness 517–520
 - receptor desensitization process 517–518
 - relationship between serotonin and NE 517–520
 - role of NE in antidepressant effects 363–364
 - serotonin uptake blockers 516–520
 - time lag for onset of activity 517–518
- antidepressant drug treatments
 - α adrenoceptor blocking effects 525, 526, 528
 - antiepileptic effects 462–463
 - clinical differences between SSRIs and NRIs 372, 374
 - clinical effects of blocking NE transporter and receptors 527–530
 - discovery and development 372, 374
 - effects of NE selective reuptake inhibitors 104–106, 107, 112
 - effects of prolonged use on NET activity 131
 - effects on β adrenergic receptors 79, 87
 - effects on noradrenergic receptors and signal transduction pathways 104–106, 107, 112
 - imipramine 535
 - induction of c-Fos 113–114
 - mediation by α_2 adrenergic receptors 76–77, 85
 - modulation of LC activity 60
 - regulation of c-Fos and IEG expression 112–113
 - role of CREB 109
 - role of CREB in adult neurogenesis 110–111, 112
 - targeting of noradrenergic neurotransmission 287–290
 - therapeutic mechanisms 372, 374
 - up-regulation of adult neurogenesis 110–111, 112
 - use in treatment of anxiety disorders 535
- antiepileptic drugs, antidepressant effects 462–463
- antipsychotic drugs
 - α adrenoceptor blocking effects 525, 527, 529
 - clinical effects of blocking NE transporter and receptors 527–530
 - mechanisms 85–86
- anxiety disorders
 - antidepressant targeting of noradrenergic neurotransmission 287–290
 - antidepressant treatments 535
 - genetic component 474
 - HPA axis dysregulation 473–474
 - insomnia 176–177
 - link with LC-norepinephrine dysfunction 60, 61, 69
 - NE gene-linked susceptibility 494–495
 - role of genes affecting NE homeostasis 474
 - role of NE dysregulation 275, 283–284, 285, 286, 288, 300–301, 473–474
 - role of NE neurotransmission in the amygdala 112–113
 - role of NE-LC hyperactivity 176–177
 - sleep disorders associated 176–177
 - treatment with NE reuptake inhibitors 544–547, 549–550
- AP-1 (activator protein-1) family of transcription factors 98–99
 - regulation by noradrenergic receptors 101, 103–104

631 Index

- regulation of AP-1 mediated gene transcription 112
- arousal, role of the LC-NE system 157
- asthma treatment
 - β_2 selective agonists 77–78
 - NE gene-linked response 498
- atomoxetine (selective NE reuptake inhibitor)
 - ADHD treatment 577–582, 583, 584
 - effects on NETs 124, 125
 - see also* tomoxetine
- attention state
 - focused vs. flexible 196–198
 - modulation by LC activity 196–198
 - selective vs. scanning 196–198
- autism, hyperphasic LC activity 220–221
- basolateral complex of the amygdala (BLA),
 - role in memory consolidation 244–245, 247–248, 249–250, 251–254, 256, 257, 259, 260, 261
- bed nucleus of the stria terminalis (BNST)
 - effects of stress-induced NE release 280–281, 282, 283
 - mediation of substance withdrawal symptoms 617–618
 - role in stress-induced drug relapse 618–620
- behaviour and psychiatric diseases, NE
 - gene-linked susceptibility 493–496
- behavioural flexibility, modulation by LC activity 196–198
- benzodiazepines, withdrawal effects on LC activity 56
- β adrenergic receptors
 - β_1 physiological roles 80, 83, 86–87
 - β_1 polymorphisms 88
 - β_2 physiological roles 80, 83, 86–87
 - β_2 polymorphisms 88
 - β_2 selective agonists in treatment of asthma 77–78
 - β_3 physiological roles 88–89
 - β_3 polymorphisms 89
 - densities in brain tissues 83, 87
 - desensitization (tachyphylaxis) 78–79
 - effects of antidepressant drugs 79
 - G protein activation 80, 81–82
 - genes 479, 488–489
 - historical development of classification 69
 - molecular characteristics 73, 78
 - nonsubtype selective agonists 77–78
 - nonsubtype selective antagonists 77, 78
 - pharmacological characteristics 77–78
 - physiological roles 80, 83, 86–89
 - regulation 78–79
 - regulation of cAMP-CREB cascade 97, 100–102
 - signal transduction pathways 80, 81–82
 - subtype selective agonists 77–78
 - subtype selective antagonists 77, 78
- bipolar disorder
 - excessive NE activity 421–422
 - prefrontal cortex dysfunction 421–422
 - protein kinase C (PKC) activity 421–422
- blood pressure
 - effects of α_2 adrenergic receptors 83–84, 85
 - role of α_1 adrenergic receptors 80, 82
- BNST *see* bed nucleus of the stria terminalis
- brain, regulators of gene expression 95 *see also* CNS
- brain development, primary functions of NE 299
- brain function, role of α_1 adrenergic receptors 82–83
- brain mapping, use of IEGs 112
- brain mapping during stress, use of IEGs 113–114
- brain tissues, densities of α_1 adrenergic receptors 82–83
- breast cancer risk, NE gene-linked susceptibility 498
- bulimia nervosa
 - NE metabolism 599–603
 - NE pharmacology in treatment 604–605
 - research on NE and feeding 595–597
- bupropion, ADHD treatment 574–577, 578–579
- c-Fos (immediate early gene; IEG) 103–104
 - expression regulation by desipramine 112–113
 - induction by antidepressants 113–114
 - induction by stress 113–114
 - NE regulation under stress conditions 113–114
 - use for brain mapping 112
 - use for brain mapping during stress 113–114
- c-Fos mediated gene transcription, regulation by NE 112–114
- cAMP-CREB cascade *see also* CREB
 - effects of NE selective reuptake inhibitors 105–106, 107, 109
 - increase in adult neurogenesis 110–111, 112
 - regulation by noradrenergic receptors 97, 100–102
 - role in learning and memory 114–115
- cAMP signaling pathway 100
- cardiovascular disease
 - heritability of onset and severity 474–476
 - NE gene-linked susceptibility 496–497
 - role of compromised NET function 134–135
- catechol-O-methyltransferase gene 479, 486–487
- catecholamine-containing neurons, classification 436–437, 438
- catecholamine dysregulation, in ADHD 179
- catecholamine neurotransmitters 1
- central nucleus of the amygdala, effects of stress-induced NE release 280–281, 282, 283
- cerebral cortex
 - influence of NE on functions 408
 - light deprivation-induced loss of NE 173–174
 - NE innervation 408–409
 - see also* prefrontal cortex; posterior and subcortical function
- chlorpromazine 515

632 Index

- cholinergic system
 - effects on memory 258–260, 261
 - interaction with the amygdala noradrenergic system 258–260, 261
- circadian regulation, role of the LC-NE system 157
- circadian sleep-wake regulation, role of LC 167–169, 171, 172, 173, 174
- clonidine, growth hormone response 365–366
- CNS disorders, link with LC-norepinephrine dysfunction 60, 61, 69
- CNS function, role of α_1 adrenergic receptors 82–83 *see also* brain
- cocaine, effects on NET activity 124, 125, 131 *see also* substance abuse
- cognitive disorders with altered NE 411, 415–424
 - ADHD 418–420
 - Alzheimer’s disease 416
 - depression 420–421
 - disorders with too little NE 415–421
 - disorders with too much NE 411, 421–424
 - Korsakoff’s amnesia 417
 - mania/bipolar disorder 421–422
 - normal aging process 415–416
 - Parkinson’s disease 417
 - PTSD 411, 423–424
 - role of NE in etiology and treatment 411, 415–424
 - schizophrenia 422–423
- cognitive functions
 - effects of stress-induced NE 414–415
 - in the prefrontal cortex 409–410, 411, 412
 - influences of NE 408
 - mediation by α_2 C adrenergic receptors 80, 85–86
- cold sensitivity, role of β_3 adrenergic receptors 88–89
- complex diseases
 - role of inherited gene variation 472–473
 - susceptibility loci 472–473
- corticotropin-releasing factor *see* CRF
- CREB (cAMP response element binding protein)
 - antidepressant effects in behavioural models 109
 - family of transcription factors 98–99
 - up-regulation of adult hippocampal neurogenesis 110–111, 112
- CREB-mediated gene transcription, activation by noradrenergic receptors 102–103
- CRF (corticotropin-releasing factor)
 - expression and receptors in the LC 21–22
 - role in noradrenergic regulation of sleep-wake cycle 166, 167, 168
 - role in stress-related sleep disorders 175–176
- CRF system, interactions with the NE system 299–300
- decision-related LC neuronal activity in monkeys 211–212, 213, 214
- dementia
 - inflammatory component 464
 - loss of LC neurons 223–224
 - role of NE 463, 464
 - specific patterns of LC neuronal loss 463, 464
- depression 85–86
 - and insomnia 174–175
 - and sleep deprivation 176
 - antidepressant drug mechanisms 76–77
 - antidepressant effects of antiepileptic drugs 462–463
 - antidepressant targeting of noradrenergic neurotransmission 287–290
 - cognitive effects 420–421
 - compromised NET function 134–135
 - effects of stress exposure 420–421
 - genetic component 474
 - hippocampal cell atrophy and cell loss 110–111, 112
 - HPA axis dysregulation 473–474
 - hypotonic LC activity 206, 221–222
 - interactions affecting sleep 175–176
 - LC cell loss 17
 - LC NE receptor imbalance 17–18
 - LC role in sleep alterations 174–176
 - NE dysregulation 60, 61, 69, 175, 275, 283–284, 285, 286, 288, 300–301, 420–421, 473–474
 - NE gene-linked susceptibility 494–495
 - prefrontal cortex dysfunction 420–421
 - regulation of α_2 adrenergic receptors 76–77
 - relationship with epilepsy 462–463
 - role of genes affecting NE homeostasis 474
 - sleep disorders 174–175
 - see also* mood disorders
- depression postmortem research
 - α_2 adrenergic receptors 351–352
 - β adrenergic receptors 352–353
 - locus coeruleus studies 346–350, 356
 - postsynaptic markers in depression 351–353
 - presynaptic markers in depression 346–350, 356
 - role of the noradrenergic system 344–353
- depression treatments
 - clinical characteristics of responders 539–542
 - comparative efficacy of NE selective antidepressants 538–539
 - evidence for use of NE reuptake inhibitors 538
 - mechanism of action 536
 - NE reuptake inhibitors 536–539, 542, 543, 544
 - reboxetine 536
 - second generation NE reuptake inhibitors 536
 - secondary or demethylated tricyclic compounds 536
 - synergistic effects of NE and 5-HT antidepressants 543–544
 - tetracyclic compounds 536
 - tomoxetine 536
 - tricyclic compounds 536
- desipramine (tricyclic antidepressant)
 - effects on NETs 124, 125
 - regulation of c-Fos and IEG expression 112–113

633 Index

- diabetes
 - effects on LC neuronal responses 56
 - NE gene-linked susceptibility 497–498
 - role of β_3 adrenergic receptors 88–89
- dopamine
 - effects on LC activity 55
 - role in substance abuse 610–611
 - transport by NETs 122
- dopamine β -hydroxylase gene 479, 485
- dopamine transporter (DAT) 120–121, 124, 125
- dopaminergic neurons
 - activity regulation by NE 59–60
 - innervation of the LC 55
 - origins of 55
- dorsal raphe nucleus
 - axonal projection to the pericoerulear area 53
 - LC reciprocal noradrenergic innervation 59, 60
- dorsomedial hypothalamus (DMH), role in sleep-wake regulation 157
- drug abuse *see* substance abuse
- DSP4 treatment, effects on sleep-wake regulation 159, 162, 163–164, 165, 167
- dysphoria and affective disorders, NE gene-linked susceptibility 494–495 *see also* depression
- eating disorders
 - NE metabolism in anorexia nervosa 597–599
 - NE metabolism in bulimia nervosa 599–603
 - NE pharmacology in treatment of anorexia nervosa 603
 - NE pharmacology in treatment of bulimia nervosa 604–605
 - research on NE and feeding 595–597
- electroconvulsant shock, effects on β adrenergic receptors 79
- electrotonic coupling among LC neurons 196–198
 - regulatory inputs 213–216, 217, 218
- emotional/stress memories, role of NE 114–115
- enkephalin expression and receptor subtypes in the LC 19–21
- environmental sensitization and NE, stress vulnerability 286–287, 288
- epilepsy
 - antiepileptic effects of antidepressants 462–463
 - antiepileptic role of the LC 454
 - clinical correlates for NE involvement 462–463
 - involvement of NE 441, 444, 454–463
 - kindling and NE activity 454–455
 - NE role in breeding to epileptic phenotype models 459
 - NE role in experimental limbic status epilepticus 441, 456–457
 - NE role in modulation of seizures 462–463
 - NE role in selective gene manipulation models 444, 459–462
 - NE system in seizure models of epilepsy 455–456
 - plasticity-dependent antiepileptic effects of NE 466
 - pro- and anticonvulsant effects of adrenergic receptor agonists 457–459
 - pro- and anticonvulsant effects of adrenergic receptor antagonists 457–459
 - relationship with depressive disorders 462–463
 - vagus nerve stimulation (VNS) treatment 462–463
- epinephrine (EPI)
 - effects on memory consolidation 238–240
 - mediation by adrenergic receptors 68
 - transport by NETs 122
- epinephrine-induced memory enhancement, mediation by the amygdala 243–244
- ERK (extracellular regulated protein kinase) signaling pathway 100
- fear, role of NE neurotransmission in the amygdala 112–113
- Fos family of AP-1 transcription factors 103–104
- frontal cortex, axonal projection to the pericoerulear area 53
- G protein-coupled receptor subtypes, NE coupling 100, 101
- G protein-coupled receptors, adrenergic receptors 68–69
- GABA (gamma amino-butyric acid)
 - effects on LC neuronal activity 56
 - expression and receptors in the LC 18
 - receptors on LC neurons 56
 - regulation of norepinephrine in the cerebral cortex 56
- GABA-containing fibers
 - innervation of the LC 56
 - origins of 56
- GABAergic system, effects on memory 258
- galanin expression and receptor types in the LC 18–19, 20
- gene expression, effects of NE reuptake inhibitors 104–106, 107, 112
- gene expression in the brain, regulation by NE 95
- gene transcription mechanisms 96–100
 - AP-1 (activator protein-1) family of transcription factors 98–99
 - cis*-regulatory elements 96–97, 98
 - CREB family of transcription factors 98–99
 - initiation of gene transcription 96–97, 98
 - messenger RNA synthesis 96–97, 98
 - posttranscriptional processing of mRNA 98
 - RNA editing 98
 - RNA half-life modulation 98
 - splice variants 98
 - TATA box 96–97, 98
 - transcription factors 98–99, 100
 - trans*-regulatory elements 97
- gene variation
 - role in common complex diseases 472–473
 - susceptibility loci for complex diseases 472–473
- generalized anxiety disorder (GAD)
 - sleep disorders associated 176–177
 - treatment with NE reuptake inhibitors 548–549
- genes *see* noradrenergic genes

634 Index

- genetic evidence for NE regulation of memory
 - consolidation 242–243
- genetic factors in ADHD 561–562
- genetically variant traits, influence of
 - noradrenergic dysfunction 473–477
- genetics tools 472–473
 - forward genetics using candidate genes 472–473
 - positional cloning (reverse genetics) using
 - linkage to markers 472–473
- glucocorticoid hormones, effects on memory
 - 253–254, 256, 257
- glutamate
 - effects on noradrenergic neurons in the LC
 - 56–57
 - inputs to the LC 56–57
 - regulatory effects on LC activity 56–57
 - sources of input to the LC 57
 - stress-associated activation of the LC 57
- growth hormone response to clonidine 365–366
- heart
 - functions of α_1 adrenergic receptors 82
 - functions of β adrenergic receptors 80,
 - 86–87
- hippocampus, memory consolidation 252–253
- hippocampus/entorhinal complex, effects of NE
 - on memory consolidation 260–264
- HPA (hypothalamic-pituitary-adrenal) axis
 - dysregulation in anxiety and depression
 - 473–474
 - stress-induced activation 278, 279
- hypnotizability, NE gene-linked susceptibility
 - 498
- hypothermic effects, mediation by α_2 adrenergic receptors 80, 84
- IEG (immediate early gene) transcription factors
 - effects of NE 112–114
 - effects of NE reuptake inhibitors 112–114
- IEGs (immediate early genes)
 - c-Fos 103–104
 - expression regulation by desipramine 112–113
 - use in brain mapping 112
 - use in brain mapping during stress 113–114
- imipramine 515–517
 - actions on the noradrenergic system 535
 - discovery of antidepressant action 535
 - NE gene-linked susceptibility 493–494
 - pharmacology 535
 - treatment of panic disorder 544–545
- insomnia
 - in anxiety disorders 176–177
 - in depression 174–175
 - mechanisms of sleep disruption 180–181
- insular cortex, effects of NE on taste aversion
 - memory 264–265
- ischemia, effects on NET function 134–135
- Jun family of AP-1 transcription factors 103–104
- Korsakoff's amnesia, cognitive deficits 417
- lateral reticular nucleus of the medulla 393
- LC (locus coeruleus)
 - acetylcholine expression and receptor
 - distribution 18
 - alternative names for 9
 - attention states regulation (focused vs. flexible)
 - 196–198
 - axon collaterals 16
 - axon-like plexuses 16
 - brain processes affected by 41
 - cell loss in Alzheimer's disease 17, 18–19, 20,
 - 180, 223–224
 - cell loss in dementia 223–224
 - cell loss in depression 17
 - cell loss in Parkinson's disease 223–224
 - cell loss with age in humans 17, 180
 - cell numbers within human LC 13–14
 - cell population heterogeneity 15–17
 - cellular changes in Alzheimer's disease 19
 - CRF expression and receptors 21–22
 - degeneration in neurological disorders 438–439
 - enkephalin and receptor subtypes 19–21
 - enkephalin coexpression by GABAergic terminals 18
 - Falck-Hillarp method of identification 10
 - functional anatomy 436–437, 438
 - fusiform cells 15–16
 - GABA expression and receptor types 18
 - GABA inhibition during REM sleep 56
 - galanin expression and receptor types 18–19,
 - 20
 - history of discovery 9–10
 - human LC neuronal subtypes 17
 - in primates 12–14
 - in the cat 11–12
 - in the rat 10–11
 - indirect projection from the SCN 167–169, 170
 - lack of pigmentation in lower species 9
 - location and extent in humans 10, 13–14
 - mediation of substance withdrawal symptoms
 - 616–618
 - morphology of human LC neurons 17
 - morphology of neurons 15–17
 - multipolar cells 15–16
 - NE provision for the CNS 53
 - NE receptor imbalance in depression 17–18
 - NE receptor subtypes 17–18
 - neuronal activity in sleep-wake regulation 159,
 - 160–164, 165, 167
 - neuropeptide Y expression and receptors 19
 - neuropeptides 18–20, 22
 - neurophysin 21
 - neurotensin 21
 - noradrenergic activation of the amygdala 237
 - noradrenergic input to the cortex 408–409
 - ontogeny 15
 - organizational pattern of catecholamine neurons 13–14
 - peri-LC dendritic arrays 16–17
 - pigmentation and immunoreactivity 13–14, 17
 - pigmentation development 12–13

635 Index

- presynaptic profile subtypes 17
- receptor subtypes and distribution 17–22
- reciprocal relationships with other parts of the brain 60, 61, 69
- role in ADHD pathophysiology 563–564
- role in arousal 157, 161–162, 196–198
- role in circadian sleep–wake regulation 159, 160–164, 165, 167–169, 171, 172, 173, 174
- role in memory consolidation 237, 241–242
- role in noradrenergic pain modulation 393–394
- role in sleep alterations due to clinical pathologies 174–181
- role in sleep alterations in depression 174–176
- role in task performance and selective attention 196–198
- selective actions of NE 40–41
- somatostatin 21
- species comparisons 10–14
- substance P 21
- substance P receptors 58–59
- synchronous activation 41
- transmitter agents 17–22
- ultrastructural features of neurons 16–17
- variable impacts of NE 41
- vasoactive intestinal peptide 21
- vasopressin 21
- LC activity
 - and task performance 196–198
 - circadian rhythm 170, 171
 - effects of acetylcholine 57–58
 - effects of aging 180
 - effects of dopamine 55
 - effects of GABA 56
 - effects of glutamate 56–57
 - effects of nicotine 58
 - effects of serotonin 54–55
 - effects of substance P 58–59
 - in sleep–wake regulation in primates 161
 - mediation by muscarinic acetylcholine receptors 57–58
 - mediation by nicotinic acetylcholine receptors 57–58
 - metabotropic glutamate receptor activation 57
 - modulation by antidepressants 60
- LC activity modes
 - clinical implications 206, 219–225
 - dysregulated phasic activity in schizophrenia 222–223
 - electrotonic coupling regulatory inputs 213–216, 217, 218
 - hyperphasic activity in autism 220–221
 - hypertonic activity in ADHD 179, 219–220
 - hypertonic activity in posttraumatic stress disorder 220
 - hypoactive mode 218
 - hypotonic activity in depression 206, 221–222
 - implications for new pharmacotherapies 224–225
 - LC dysfunction and sleep disorders 224
 - link with decision to respond 218–219
 - pharmacological regulation 224–225
 - phasic LC mode 218
 - relationship to attention 218–219
 - theory of modes of activity 218
 - tonic activity variation with arousal states 160–161, 199
 - tonic LC mode 218
- LC afferent input sources 22–25, 26
- acetylcholine-containing neurons 57–58
- anterograde studies 22, 23–24
- dopaminergic innervation 55
- glutamate 56–57
- innervation by GABA-containing fibers 56
- innervation by substance P-containing fibers 58–59
- input from other brain regions 53
- input from the PGI 53
- input from the PrH 53
- peri-LC dendritic contacts 24–25, 26
- retrograde studies 22–23
- serotonergic innervation 54–55
- ultrastructural examinations 24–25, 26
- LC chemoarchitecture (neurochemically identified pathways) 31–39, 40, 61
- adrenergic inputs 33
- afferent inputs 31–38, 39, 61
- CRF inputs 35–36
- dopaminergic inputs 33
- efferent connections 38–40
- efferent target selectivity 40–41
- enkephalin inputs 36
- excitatory inputs 31–32
- GABA inhibitory inputs 32–33
- glutamate receptors 31–32
- glutamatergic excitatory inputs 31–32
- glycine inhibitory inputs 32–33
- hypocretins 34–35
- inhibitory inputs 32–33
- neuropeptide inputs 34–38, 39, 61
- noradrenergic inputs 33
- orexin A and B 34–35
- preprohypocretin (hcrt) 34–35
- serotonergic inputs 33
- synchronous activation 41
- LC efferent projection 26–28, 29, 30, 31
- axon collateralization 28–29, 30, 31
- global network of NE neurons 198
- histochemistry and anterograde labeling 26–27
- modulation of target area neuronal activity by NE 198–199
- neuron innervation of more than one structure 28–29, 30, 31
- reciprocal projection of noradrenergic fibers 59–60
- retrograde labeling 28, 29, 30
- LC lesions
 - effects on circadian amplitude of sleep–wake cycle 170–173
 - effects on sleep–wake regulation 159, 162, 163–164, 165, 167

Cambridge University Press

978-0-521-83491-9 - Brain Norepinephrine: Neurobiology and Therapeutics

Edited by Gregory A. Ordway, Michael A. Schwartz and Alan Frazer

Index

[More information](#)

636

Index

- LC neuronal activity, influence of prefrontal cortex 213–215, 216, 217
- LC neuronal activity and task performance (monkeys) 200–202, 204, 206
 - complexity of relationship with vigilant behaviour 205–206
 - hypoactive mode 205–206
 - interpretation of results 205–206
 - modes of LC activity 205–206
 - phasic activation by meaningful stimuli 201, 202
 - phasic mode 205–206
 - relationship of tonic to phasic activity 203–204, 205
 - target detection task 200
 - task difficulty 205
 - tonic fluctuations during task performance 202–203, 204
 - tonic mode 205–206
- LC neuronal activity and task performance (simulation model) 206–207, 209, 210
 - components of the model 206–207
 - electrotonic coupling 208–209
 - interpretation of results 210
 - LC model 208, 209
 - questions addressed 206–207
 - simulation results 209–210
 - stimulus discrimination network 207–208
- LC neuronal activity in decision making (monkeys) 211–212, 213, 214
 - forced-choice task 211
 - phasic activation of the LC 211–212, 213, 214
- LC neurons
 - activation by stressors 199–200
 - activity in relation to task performance 196–198
 - circadian fluctuations in activity 157
 - disease specific patterns of neuronal loss 463
 - electrotonic coupling 196–198
 - GABA receptors 56
 - modes of functioning 196–198
 - phasic and tonic activity 196–198
 - phasic responsiveness 199–200
 - polymodal sensory responsiveness 199–200
 - ultrastructural features 16–17
- LC-NE dysregulation
 - and depression 175
 - hyperactivity in anxiety disorders 176–177
 - hyperactivity in PTSD 178–179
 - link with depression and anxiety 60, 61, 69
 - role in stress-related sleep disorders 175–176
 - see also specific disorders*
- learning
 - role of cAMP-CREB cascade 114–115
 - role of NE 114–115, 236–237
- Lewy body disease 463
- light deprivation, loss of cortical NE 173–174
- locus coeruleus *see* LC
- long-term memory *see* memory consolidation
- long-term potentiation, role of NE 466
- lymphocytes, NE receptors on 364–365
- mania
 - excessive NE activity 421–422
 - prefrontal cortex dysfunction 421–422
 - protein kinase C (PKC) activity 421–422
- MAP kinase signaling pathway 100, 102–103
- medial prefrontal cortex, effects of NE on working memory 264
- memory
 - age-related memory loss 415–416
 - brain systems involved in 236–237
 - development of chronic stress symptoms 265–266
 - effects of activation of the noradrenergic system 265–266
 - effects of emotional arousal 265–266
 - modulation by central NE function 236–237
 - NE role in long-term consolidation 236–237
 - noradrenergic activation of the amygdala 237
 - role of cAMP-CREB cascade 114–115
 - role of NE 114–115
 - see also* working memory
- memory consolidation
 - effects of amphetamine 238–240
 - effects of epinephrine 238–240
 - effects of LC noradrenergic system 241–242
 - effects of NE on hippocampus/entorhinal complex 260–264
 - effects of NE on insular cortex 264–265
 - effects of NE on medial prefrontal cortex 264
 - factors affecting strength of memories 238
 - genetic evidence for NE regulation 242–243
 - influence of amygdala noradrenergic system 243–246, 247, 248, 250, 253
 - influence of emotional arousal 238
 - NE effects on human subjects 265–266
 - peripheral epinephrine and norepinephrine effects 240
 - pharmacological evidence for NE regulation 242–243
 - role of adrenergic catecholamines 238–243
 - role of brain stem noradrenergic cell groups 240–242
 - role of the basolateral complex of the amygdala 244–245, 247–248, 249–250, 251–254, 256, 257, 259, 260, 261
 - role of the nucleus of the solitary tract 240–242
 - see also* amygdala noradrenergic system
- metabolic disorders, NE gene-linked susceptibility 497–498
- methylphenidate treatment for ADHD 563
- migraine, NE gene-linked susceptibility 493
- monoamine oxidase genes 479, 486
- monoamine oxidase inhibitors (MAOIs)
 - ADHD treatment 572, 573
 - introduction of 515–517
- mood disorders
 - antidepressant drug mechanisms 372, 374
 - biological theories 372, 374
 - clinical differences between SSRIs and NRIs 372, 374

637 Index

- discovery and development of treatments 372, 374
- effects of neurotransmitter depletion challenges 366–372
- research into the role of NE 363–364
- role of NE in illness 374–376
- role of NE in treatment 374–376
- see also* depression
- movement disorders, NE gene-linked susceptibility 489–493
- multiple sclerosis 463, 465
- multiple systems atrophy (MSA) 463–464
- muscarinic acetylcholine receptors, mediation of LC activity 57–58
- narcolepsy, NE gene-linked susceptibility 498
- NE (norepinephrine)
 - age-related decrease in clearance 133–134
 - and environmental sensitization 286–287, 288
 - chemical “switch” 414–415, 424
 - coupling to G protein-coupled receptor subtypes 100, 101
 - CRF system interactions 299–300
 - discovery of 1
 - effects of GABA on levels in LC 56
 - effects on IEG transcription factors 112–114
 - effects on stress vulnerability 286–287, 288
 - functional anatomy of central NE system 436–437, 439
 - influence on the amygdala 112–113, 243–246, 247, 248, 250, 253
 - influence on fear and anxiety states 112–113
 - influence via reciprocal projections from the LC 60, 61, 69
 - modulation of activity in LC target areas 198–199
 - modulatory effects on brain circuits 275–276
 - nicotine-stimulated release 58
 - primary functions during brain development 299
 - primary functions in the mature CNS 299–300
 - provision by the LC 53
 - regulation by neurotransmitter inputs to the LC 53
 - regulation of AP-1 family of transcription factors 98–99
 - regulation of c-Fos gene expression 112–113, 114
 - regulation of c-Fos under stress conditions 113–114
 - regulation of CREB family of transcription factors 98–99
 - regulation of neuronal gene expression 95
 - regulation of serotonergic raphe nuclei 59, 60
 - role in clinical anesthesia 396–397
 - role in etiology and treatment of cognitive disorders 411, 415–424
 - role in learning 114–115, 236–237
 - role in long-term memory consolidation 236–237, 240, 242–246, 247, 248, 250, 253
 - role in long-term potentiation 466
 - role in memory 114–115, 409–410, 411, 412
 - role in mood disorders 300–301, 374–376
 - role in neural development 325
 - role in pathogenesis of neurological disorders 438–439
 - role in stress-induced HPA axis activation 279
 - role in treatment of mood disorders
 - role in vigilance and attention 58
 - signal transduction pathway activation 100–101, 104
 - systemic effects in response to stress 275–276
 - widespread innervation and influence 275–276
- NE dysregulation
 - in ADHD 179
 - link with depression and anxiety 60, 61, 69
 - see also* neurological disorders and NE
- NE gene-linked susceptibilities 489–492, 498
 - addictions 496
 - ADHD 493–494
 - Alzheimer’s disease 493
 - anxiety 494–495
 - asthma treatment response 498
 - behaviour and psychiatric diseases 493–496
 - breast cancer risk 498
 - cardiovascular disorders 496–497
 - counterbalancing selective benefits 498–499
 - diabetes 497–498
 - dysphoria and affective disorders 494–495
 - hypnotizability 498
 - impulsivity 493–494
 - metabolic disorders 497–498
 - migraine 493
 - movement disorders 489–493
 - narcolepsy 498
 - neurodegenerative disease 493
 - neurological disorders 489–493
 - obesity 497–498
 - pain 493
 - Parkinson’s disease 489–493
 - prefrontal cortex dysfunction 495–496
 - schizophrenia 495–496
- NE genetic factors
 - in anxiety disorders 474
 - in cardiovascular disease 474–476
 - in depression 474
 - in pain processing
 - in respiratory diseases 474–476
- NE metabolic pathways
 - MHPG marker 364
 - peripheral and central markers 364
 - see also* LC chemoarchitecture
- NE receptors
 - on lymphocytes 364–365
 - on platelets 364–365
 - see also* adrenergic receptors; noradrenergic receptors
- NE reuptake
 - termination of action 119
 - uptake-1 (neuronal uptake) 119
 - uptake-2 (nonneuronal uptake) 119

638 Index

- NE reuptake inhibitors 287–290
 - anxiety disorder treatments 544–547, 549–550
 - clinical characteristics of responders 539–542
 - clinical comparison with SSRIs 372, 374
 - comparative efficacy of NE selective antidepressants 538–539
 - effects on cAMP-CREB cascade 105–106, 107, 109
 - effects on gene expression 104–106, 107, 112
 - effects on IEG transcription factors 112–114
 - effects on NETs 124, 125
 - effects on transcription factors 104–106, 107, 112
 - evidence for use in depression 538
 - generalized anxiety disorder treatment 548–549
 - imipramine 535
 - mechanism of action 536
 - obsessive-compulsive disorder treatment 546–547
 - panic disorder treatment 544–545
 - PTSD treatment 549
 - reboxetine 536
 - second generation compounds 536
 - secondary or demethylated tricyclic compounds 536
 - social anxiety disorder treatment 549
 - synergistic effects of NE and 5-HT antidepressants 543–544
 - tetracyclic compounds 536
 - tomoxetine 536
 - treatment of depression 536–539, 542, 543, 544
 - tricyclic compounds 536
 - up-regulation of hippocampal neurogenesis 110–111, 112
- NE selective reuptake inhibitors *see* NE reuptake inhibitors
- NE transcription
 - mediation by AP-1 family of transcription factors 98–99
 - mediation by CREB family of transcription factors 98–99
- NET (norepinephrine transporter) 119
 - active transport function 122–123
 - acute regulation of neuronal NE uptake 127–130
 - age-related alterations in function 133–134
 - alternating-access mode 125–126
 - blocking effects of psychotropic drugs 520–522, 523, 524, 525
 - channel mode 125–126
 - chronic regulation of neuronal NE uptake 127–128, 131
 - clinical effects of blocking by antidepressants 527–530
 - clinical effects of blocking by antipsychotics 527–530
 - control of NE homeostasis 123
 - distribution of NETs 121–122
 - effects of prolonged exposure to psychoactive agents 131
 - effects of psychoactive drugs 124, 125
 - effects on NE function 122–123
 - factors affecting NET activity 127–128, 131
 - gateway for NE metabolism and recycling 123
 - human NET (hNET) 120–121
 - identification in various species 120–121
 - mechanism of NE uptake 124–126, 127
 - molecular structure 120–121
 - NE reuptake into presynaptic neurons 122–123
 - regional variations in extent of NE recapture 123
 - regulation of NE uptake 127–128, 131
 - role in synaptic plasticity 123
 - role of compromised function in disease 134–135
 - targets for drugs 124, 125
 - transmembrane topology 120–121
 - transport of other catecholamine neurotransmitters 122
- NET-associated proteins 131–132
- NET genes 477–478, 479, 485–486
 - polymorphisms (coding and noncoding) 133
 - splice variants 132–133
- neurodegenerative disease, NE gene-linked susceptibility 493
- neuroendocrine challenges, growth hormone response to clonidine 365–366
- neurogenesis, up-regulation by NE selective reuptake inhibitors 110–111, 112
- neurological disorder modelling
 - markers to assess damage to NE pathways 441–442, 444, 445
 - tools to damage central NE pathways 437, 439–441, 442, 443
- neurological disorders and NE 441, 444, 445–466
 - Alzheimer’s disease 463, 464
 - dementia 463, 464
 - disease specific patterns of LC neuronal loss 463
 - epilepsy 441, 444, 454–463
 - functional anatomy of central NE system 436–437, 439
 - Lewy body disease 463
 - multiple sclerosis 463, 465
 - multiple systems atrophy (MSA) 463–464
 - NE gene-linked susceptibility 489–493
 - Parkinson’s disease 445–454
 - Pick’s disease 463
 - protective role of NE 466
 - role of NE in pathogenesis 438–439
 - sleep disorders 465–466
- neurophysin, in the LC 21
- neurotensin, in the LC 21
- neurotransmitter depletion challenges
 - AMPT inhibitor 366–367, 368–372
 - catecholamine depletion 366–372
 - effects on mood disorders 366–372
 - results 368–372
 - synthesis inhibition by dietary means 367–368
 - synthesis inhibition by pharmacological means 366–367
- neurotransmitter depletion studies 363–364

639 Index

- nicotine
 - effects on LC activity 58
 - stimulation of norepinephrine release 58
 - see also* substance abuse
- nicotinic acetylcholine receptors, mediation of LC activity 57–58
- noradrenergic dysfunction
 - and HPA axis dysregulation 473–474
 - cardiovascular and respiratory effects 474–476
 - influence in anxiety/dysphoria domain 473–474
 - influence on genetically variant traits 473–477
 - influence on pain processing 476–477
 - underlying influence of stress 473
- noradrenergic genes
 - α_1 adrenergic receptors 479, 487
 - α_2 adrenergic receptors 479, 487–488
 - β adrenergic receptors 479, 488–489
 - biosynthetic genes 477–485
 - catechol-O-methyltransferase 479, 486–487
 - counterbalancing positive effects 498–499
 - dopamine β -hydroxylase 479, 485
 - identification in the human genome 477–478
 - metabolizing genes 477–478, 479, 485–487
 - missense substitutions 477–478, 480–484
 - monoamine oxidase 479, 486
 - NE receptor genes 477–478, 479, 487–489
 - NET genes 477–478, 479, 485–486
 - structural variations 477–484, 489
 - tyrosine hydroxylase 478–485
- noradrenergic neurons
 - acetylcholine receptors 57–58
 - effects of acetylcholine 57–58
 - effects of dopamine 55
 - effects of GABA 56
 - effects of glutamate 56–57
 - effects of substance P 58–59
 - functional relationship with serotonergic neurons 54–55
 - innervation by GABA axon terminals 56
 - projection from the LC 59–60
 - regulation of dopaminergic output of the ventral tegmental area 59–60
 - regulation of serotonin release in the raphe 59, 60
- noradrenergic neurotransmission
 - effects of chronic NE reuptake blockade 287–290
 - effects of selective pharmacological enhancement 287–290
 - pharmacological effects on tonic and phasic activity 287–290
 - phasic activation in response to stress 277–279
 - regulatory target of antidepressants 287–290
 - tonic elevation with arousal 276–277
- noradrenergic neurotransmitter system
 - modulatory effects on brain circuits 275–276
 - potential substrate for stress vulnerability 283–284, 285, 286, 288
 - systemic effects in response to stress 275–276
 - widespread innervation and influence 275–276
- noradrenergic pain modulation, interactions with other neurotransmitters 395–396
- noradrenergic pain modulation (peripheral mechanisms) 385–387
 - conflicting evidence 387
 - pain facilitation by peripheral α_2 adrenoceptors 386, 387
 - pain inhibition by peripheral α_2 adrenoceptors 386–387
 - plasticity following injury or inflammation 385–386
- noradrenergic pain modulation (spinal mechanisms) 387–392
 - activation of pain inhibitory interneurons 392
 - in inflammatory pain 389
 - in neuropathic pain 389–390
 - in pathological conditions 389–390
 - mechanisms underlying noradrenergic analgesia 390–392
 - nociception suppression by spinal NE 387–388
- noradrenergic pain inhibitory feedback loop 388
 - postsynaptic pain inhibition 391
 - presynaptic pain inhibition 390–391
- noradrenergic pain modulation (supraspinal mechanisms) 392–394
 - lateral reticular nucleus of the medulla 393
 - locus coeruleus 393–394
 - periaqueductal gray 392
 - rostroventromedial medulla
 - thalamus 394
- noradrenergic pain modulation (sympatho-adrenal mechanisms) 395
 - adrenal medulla 395
 - in nerve injury 395
 - postganglionic sympathetic nerve fibers 395
- noradrenergic receptors
 - activation of CREB-mediated gene transcription 102–103
 - activation of signal transduction pathways 100–101, 104
 - effects of antidepressants 104–106, 107, 112
 - regulation of AP-1 family transcription factors 101, 103–104
 - regulation of cAMP-CREB cascade 97, 100–102
 - subtypes in the LC 17–18
 - see also* adrenergic receptors
- norepinephrine *see* NE
- NRIs *see* NE reuptake inhibitors
- nucleus of the solitary tract (NTS), role in memory consolidation 240–242
- nucleus paragigantocellularis (PGi), input to the LC 53
- nucleus prepositus hypoglossi (PrH)
 - input to the LC 53
 - origin of GABA-containing fibers 56
- obesity
 - NE gene-linked susceptibility 497–498
 - role of β_3 adrenergic receptors 88–89

640 Index

- obsessive-compulsive disorder (OCD)
 - sleep disorders associated 176–177
 - treatment with NE reuptake inhibitors 546–547
- opioid abuse *see* substance abuse
- opioid peptidergic system, effects on memory 256–258, 259
- orbital frontal cortex, influence on LC neuronal activity 213–215, 216, 217
- pain, NE gene-linked susceptibility 493
- pain processing
 - genetic factors
 - influence of noradrenergic dysfunction 476–477
 - mechanisms of analgesia
 - see also* noradrenergic pain modulation
- panic disorder
 - role of NE system abnormalities 300–301
 - sleep disorders associated 176–177
 - treatment with NE reuptake inhibitors 544–545
- paradoxical sleep 157–158 *see also* REM sleep
- Parkinson's disease
 - cognitive deficits 417
 - differential LC pathology in subgroups 463
 - effects of NE depletion 453–454
 - effects on the LC 445–446
 - involvement of NE 445–454
 - involvement of NE neurons (anatomical evidence) 446–447
 - involvement of NE neurons (clinical evidence) 448–450
 - involvement of NE neurons (neurochemical evidence) 447–448
 - involvement of NE neurons in experimental parkinsonism 450
 - LC neuron loss 223–224, 447, 453–454
 - NE and progression of parkinsonism 450–453
 - NE gene-linked susceptibility 489–493
 - postmortem brain research 341–342
 - role of compromised NET function 134–135
- peri-LC dendrites, afferent input sources 24–25, 26
- periaqueductal gray 392
- pericoerulear area
 - axonal projection from other brain areas 53
 - dendritic projection from LC neurons 53
- PFC *see* prefrontal cortex
- PGi *see* nucleus paragigantocellularis
- phasic noradrenergic neurotransmission
 - activation in response to stress 277–279
 - pharmacological effects on activity 287–290
- Pick's disease, specific pattern of LC neuronal loss 463
- platelets, NE receptors on 364–365
- posterior and subcortical function
 - arousal state modulation by NE 412–413
 - long-term memory consolidation 413–414
 - NE modulation of plasticity 414
 - NE regulation 410, 411, 412–414
 - stimulus processing enhancement by NE 413–414
- postmortem human brain research
 - Alzheimer's disease neuropathy 341–342
 - Parkinson's disease neuropathy 341–342
 - postsynaptic NE markers 343–344
 - presynaptic NE markers 343–344
 - role of NE in CNS disorders 341–343
 - shortcomings 342–343
 - strengths 343
 - tool to study CNS disease 341–343
- postmortem research on depression
 - α_2 adrenergic receptors 351–352
 - β adrenergic receptors 352–353
 - locus coeruleus studies 346–350, 356
 - postsynaptic markers in depression 351–353
 - presynaptic markers in depression 346–350, 356
 - role of the noradrenergic system 344–353
- postmortem research on schizophrenia
 - postsynaptic markers in schizophrenia 354–355
 - presynaptic markers in schizophrenia 353–354
 - role of the noradrenergic system 353–355
- posttraumatic stress disorder (PTSD) 85–86
 - and LC-NE hyperactivity 178–179
 - cognitive disorders 411, 423–424
 - effects of NE hyperactivity 411, 423–424
 - hypertonic LC activity 220
 - prefrontal cortex dysfunction 411, 423–424
 - role of NE 114–115
 - role of NE dysregulation 275, 283–284, 285, 286, 288, 300–301
 - role of NE in etiology and treatment 411, 423–424
 - sleep disorders 176–177, 178–179
 - treatment with NE reuptake inhibitors 549
- prefrontal cortex (PFC)
 - adrenergic receptor types and distribution 408–409
 - cognitive functions 409–410, 411, 412
 - influence on LC neuronal activity 213–215, 216, 217
 - LC reciprocal innervation 408–409
 - NE input 408–409
 - NE regulation 409–410, 411, 412
- prefrontal cortex dysfunction
 - in psychiatric illnesses 408
 - in PTSD 411, 423–424
 - NE gene-linked susceptibility 495–496
 - role in ADHD 562–563
 - see also* cognitive disorders with altered NE
- PrH *see* nucleus prepositus hypoglossi
- prostatic hypertrophy (benign), treatment 82
- protein kinase C (PKC) activity
 - in mania/bipolar disorder 421–422
 - signaling pathway 100, 102–103
- psychotropic drugs, NET blocking effects 520–522, 523, 524, 525
- PTSD *see* posttraumatic stress disorder
- reboxetine (selective NRI) 536
 - effects on NETs 124, 125
- REM (rapid eye movement) sleep
 - LC inhibition by GABA 56
 - see also* paradoxical sleep

641 Index

- reserpine, history of 516
- respiratory diseases, heritability of onset and severity 474–476
- rostromedial medulla
- schizophrenia
 - cognitive disorders 422–423
 - dysregulated LC phasic activity 222–223
 - importance of NE hyperactivity 422–423
 - mechanisms of antipsychotic drugs 85–86
 - NE gene-linked susceptibility 495–496
 - prefrontal cortex dysfunction 422–423
 - role of compromised NET function 134–135
- schizophrenia postmortem research
 - postsynaptic markers in schizophrenia 354–355
 - presynaptic markers in schizophrenia 353–354
 - role of the noradrenergic system 353–355
- SCN *see* suprachiasmatic nucleus
- sedation, mediation by α_2 adrenergic receptors 80, 84
- selective NE reuptake inhibitors (SNRIs) *see* NE reuptake inhibitors
- serotonergic activity
 - modulation of GABAergic input to the LC 56
 - regulation by NE 59, 60
- serotonergic neurons
 - functional relationship with noradrenergic neurons 54–55
 - innervation of the noradrenergic LC 54–55
 - origins of 54
- serotonin (5-HT)
 - effects on LC activity 54–55
 - transport by NETs 122
- serotonin (5-HT) transporter (SERT) 120–121, 124, 125
- signal transduction pathways
 - α_1 adrenergic receptors 79, 80
 - α_2 adrenergic receptors 79–81
 - β adrenergic receptors 80, 81–82
 - NE activation 100–101, 104
- sleep deprivation, and depression 176
- sleep disorders
 - and LC dysfunction 224
 - in depression 174–175
- sleep disorders (neurological disorders), and NE 465–466
- sleep disruption, in insomnia 180–181
- sleep rebound effect after sleep deprivation 163–164, 165, 167
- sleep-wake regulation
 - alteration due to clinical pathologies 174–181
 - brain systems involved 157–159, 160
 - effects of aging 180
 - effects of DSP4 treatment 159, 162, 163–164, 165, 167
 - effects of LC lesions 159, 162, 163–164, 165, 167
 - effects of LC lesions on circadian amplitude 170–173
 - effects of light deprivation on cortical NE 173–174
 - effects of stress response 166, 167, 168, 175–176
 - in ADHD 179
 - in anxiety disorders 176–177
 - in depression 174–176
 - in PTSD 178–179
 - LC activity and cortical arousal 161–162
 - LC involvement 159, 160–164, 165, 167
 - LC neuronal activity 159, 160–164, 165, 167
 - LC tonic activity variation with arousal states 160–161
 - mechanisms of stage transitions 159, 160
 - networks involved 158–159, 160
 - neuronal groups involved 158–159
 - paradoxical sleep 157–158
 - primate LC activity 161
 - role of CRF in noradrenergic regulation 166, 167, 168
 - role of LC in circadian regulation 167–169, 171, 172, 173, 174
 - role of LC-NE system 157
 - role of the dorsomedial hypothalamus (DMH) 157
 - role of the suprachiasmatic nucleus (SCN) 157, 167
 - sleep rebound effect after deprivation 163–164, 165, 167
 - slow wave sleep 157–158
 - spontaneous sleep 159, 162
 - wakefulness 157–158
- slow wave sleep 157–158
- SNRIs *see* NE reuptake inhibitors
- social anxiety disorder, treatment with NE reuptake inhibitors 549
- somatostatin, in the LC 21
- SSRIs
 - clinical comparison with NRIs 372, 374
 - mechanism of therapeutic effects 363–364
- steroid hormone receptor superfamily (transcription factors) 99–100
- stress
 - development of chronic stress symptoms in humans 265–266
 - effects on NE regulation of c-Fos 113–114
 - effects on serotonergic input to the LC 54–55
 - hippocampal cell atrophy and cell loss 110–111, 112
 - HPA axis activation 278, 279
 - induction of c-Fos 113–114
 - responses of the noradrenergic neurotransmitter system 275–276
- stress-associated activation of the LC
 - by glutamate 57
 - by substance P 58–59
- stress-dependent depression 85–86
- stress exposure
 - and depression 420–421
 - and NE dysregulation 420–421
 - and prefrontal cortex dysfunction 420–421
- stress-induced drug relapse and NE 618–620

642 Index

- stress-induced NE release
 - chemical “switch” 414–415, 424
 - effects on cognitive function 414–415
 - modulatory effects on stress responses 280–281, 282, 283
- stress-induced working memory deficits 412
- stress-related interactions, and sleep disorders 175–176
- stress-related memories, role of NE 114–115
- stress-related psychiatric disorders
 - antidepressant targeting of noradrenergic neurotransmission 287–290
 - role of NE dysregulation 275, 283–284, 285, 286, 288
- stress response
 - effects on sleep–wake regulation 166, 167, 168
 - modulatory effects of stress-induced NE release 280–281, 282, 283
 - phasic activation of noradrenergic neurotransmission 287–279
 - role of brain NE 275
- stress vulnerability
 - individual vulnerability factors 283–284, 285, 286, 288
 - interaction of NE and environmental sensitization 286–287, 288
 - noradrenergic system as potential substrate 283–284, 285, 286, 288
- stressors
 - activation of LC neurons 199–200
 - processive (psychogenic) 277–279
 - range of 277–279
 - systemic (physiologic) 277–279
- substance abuse
 - BNST mediation of withdrawal symptoms 617–618
 - BNST role in stress-induced drug relapse 618–620
 - definition 610–611
 - LC mediation of withdrawal symptoms 616–618
 - NE and stress-induced relapse 618–620
 - NE markers for predisposition to alcoholism 615
 - NE markers for reward dependence personality trait 615
 - NE treatment 620–622
 - role of dopamine 610–611
 - role of NE in dependence 616–618
 - role of NE in reward 611–612, 616
 - role of NE in withdrawal symptoms 616–618
- substance P
 - effects on LC activity 58–59
 - in the LC 21
- substance P antagonists, antidepressant properties 58–59
- substance P-containing fibers, innervation of the LC 58–59
- suicide, role of compromised NET function 134–135
- suprachiasmatic nucleus (SCN)
 - indirect projection to the LC 167–169, 170
 - role in sleep–wake regulation 157, 167
- synaptic plasticity, role of NET 123
- task performance, and LC activity 196–198
- thalamus 394
- tomoxetine 536 *see also* atomoxetine
- tonic noradrenergic neurotransmission
 - elevation with arousal 276–277
 - pharmacological effects on activity 287–290
- transcription factors, effects of NE selective reuptake inhibitors 104–106, 107, 112
- tricyclic antidepressants
 - ADHD treatment 566–570, 572
 - effects on NETs 124, 125
 - introduction of 515
 - targeting of noradrenergic neurotransmission 287–290
- tyrosine hydroxylase gene 478–485
- vasoactive intestinal peptide, in the LC 21
- vasopressin, in the LC 21
- venlafaxine, ADHD treatment 577, 580
- ventral tegmental area
 - axonal projection to the pericoerulear area 53
 - LC reciprocal noradrenergic innervation 59–60
 - origin of dopaminergic fibers 55
 - regulation of dopaminergic output 59–60
- wakefulness 157–158
- working memory
 - effects of stress exposure 412
 - in the prefrontal cortex 409–410, 411, 412
 - influences of NE 409–410, 411, 412